trial · primary record
Mocertatug rezetecan
Neoplasms, Endometrial
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 600 |
| Primary completion | 2029-05-30 |
| Primary endpoint | Objective response rate (ORR) by BICR |
| Registry ID | NCT07286331 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:11.478Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07286331
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Mocertatug rezetecan · compound